Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs

Cancer Gene Therapy

Volumn 11, Issue 5, 2004, Pages 389-396

  Tone, Catherine M ^a   Cardozo, Dawn M ^a   Carpenter, Robert H ^a   Draghia Akli, Ruxandra ^a  

^a ADViSYS Inc   (United States)

Author keywords

Cachexia; Dog; Electroporation; GH; GHRH; Plasmid

Indexed keywords

ANABOLIC AGENT; GROWTH HORMONE RELEASING FACTOR; SOMATOMEDIN C;

AGE DISTRIBUTION; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; APPETITE; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CACHEXIA; CANCER; CANCER PATIENT; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG SAFETY; ERYTHROCYTE COUNT; EXERCISE TOLERANCE; GERIATRIC DISORDER; GROWTH HORMONE RELEASE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; LONG TERM EXPOSURE; MUSCLE DEVELOPMENT; NONHUMAN; PHYSICAL ACTIVITY; PLASMID; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT;

AGING; ANEMIA; ANIMALS; ANOREXIA; BODY WEIGHT; CACHEXIA; DOG DISEASES; DOGS; ERYTHROCYTE COUNT; GROWTH HORMONE-RELEASING HORMONE; HEMATOCRIT; HEMOGLOBINS; INJECTIONS, INTRAMUSCULAR; INSULIN-LIKE GROWTH FACTOR I; MOTOR ACTIVITY; MUSCLE DEVELOPMENT; NEOPLASMS; PLASMIDS; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 2342477280     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700717     Document Type: Article

References (30)

1. Frederickson RM, Carter BJ, Pilaro AM. Nonclinical toxicology in support of licensure of gene therapies. Mol Ther. 2003;8:8-10.
2. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622-634.
3. Colao A, Cuocolo A, Di Somma C, et al. Impaired cardiac performance in elderly patients with growth hormone deficiency. J Clin Endocrinol Metab. 1999;84:3950-3955.
4. Wang W, Iresjo BM, Karlsson L, Svanberg E. Provision of rhIGF-I/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model. Clin Nutr. 2000;19:127-132.
5. Pichard C, Kyle UG, Jolliet P, et al. Treatment of cachexia with recombinant growth hormone in a patient before lung transplantation: a case report. Crit Care Med. 1999;27:1639-1642.
6. Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1994;78:404-410.
7. Molon-Noblot S, Laroque P, Prahalada S, et al. Effect of chronic growth hormone administration on skeletal muscle in dogs. Toxicol Pathol. 1998;26:207-212.
8. Angelopoulos TJ, Seip RL, Cole TG. Effect of short-term recombinant growth hormone administration on plasma lipoproteins in elderly adults. Gerontology. 1998;44:228-231.
9. Satozawa N, Takezawa K, Miwa T, Takahashi S, Hayakawa M, Ooka H. Differences in the effects of 20 K- and 22 K-hGH on water retention in rats. Growth Horm IGF Res. 2000;10:187-192.
10. Takahashi S, Satozawa N. The 20-kD human growth hormone reduces body fat by increasing lipolysis and decreasing lipoprotein lipase activity. Horm Res. 2002; 58:157-164.
11. Draghia-Akli R, Cummings KK, Khan AS, Brown PA, Carpenter RH. Effects of plasmid-mediated growth hormone releasing hormone supplementation in young healthy Beagle dogs. J Anim Sci. 2003;81:2301-2310.
12. Draghia-Akli R, Hahn KA, King GK, Cummings K, Carpenter RH. Effects of plasmid mediated growth hormone releasing hormone in severely debilitated dogs with cancer. Mol Ther. 2002;6:830-836.
13. Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol. 1999;17:241-245.
14. Draghia-Akli R, Fiorotto ML, Hill LA, Malone PB, Deaver DR, Schwartz RJ. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat Biotechnol. 1999; 17:1179-1183.
15. Morrison W. Clinical evaluation of cancer patients. In: Morrison W, ed. Cancer in Dogs and Cats: Medical and Surgical Management, Vol. 7. West Lafayette, IN: Teton New Media; 2002: 57-65.
16. Draghia-Akli R, Khan AS, Cummings KK, et al. Electrical enhancement of formulated plasmid delivery in animals. Technol Cancer Res Treat. 2002;1:365-371.
17. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2003;101:2563-2569.
18. High K. AAV-mediated gene transfer for hemophilia. Genet Med. 2002;4:56S-61S.
19. Fewell JG, MacLaughlin F, Mehta V, et al. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther. 2001;3:574-583.
20. Horiuchi A, Nikaido T, Mitsushita J, Toki T, Konishi I, Fujii S. Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int J Cancer. 2000;88:640-644.
21. Imai E, Isaka Y. Gene electrotransfer: potential for gene therapy of renal diseases. Kidney Int. 2002;61(Suppl 1):37-41.
22. Xue F, Takahara T, Yata Y, et al. Attenuated acute liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation. Gut. 2002;50:558-562.
23. Puche RC, Alloatti R, Chapo G. Growth and development of male "little" mice assessed with Parks' theory of feeding and growth. Growth Dev Aging. 2002;66:71-78.
24. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med. 1996;125:873-882.
25. Pan LC, Carpino PA, Lefker BA, et al. Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue. Endocrine. 2001;14:121-132.
26. Prahalada S, Stabinski LG, Chen HY, et al. Pharmacological and toxicological effects of chronic porcine growth hormone administration in dogs. Toxicol Pathol. 1998;26:185-200.
27. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf. 2002; 25:199-212.
28. Ten Have SM, van der Lely AJ, Lamberts SW. Increase in haemoglobin concentrations in growth hormone deficient adults during human recombinant growth hormone replacement therapy. Clin Endocrinol (Oxf). 1997;47:565-570.
29. Sivan B, Lilos P, Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab. 2003;16:509-520.
30. Kotzmann H, Riedl M, Clodi M, et al. The influence of growth hormone substitution therapy on erythroid and myeloid progenitor cells and on peripheral blood cells in adult patients with growth hormone deficiency. Eur J Clin Invest. 1996;26:1175-1181.